You are here

Shankha Satpathy


Satpathy S*., Krug K*., Beltran J.M.P*., Savage S*, A proteogenomic portrait of lung squamous cell carcinoma, Cell 2021 (in press). * co-first authorship

Krug K*, Jaehnig EJ* ,Satpathy S* Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy, Cell, 2020, * co-first authorship

Gillette MA*, Satpathy S*, Cao S, et al. Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma. Cell. 2020 Jul 9;182(1):200-225.e35. *Equal contribution

Satpathy S, Jaehnig EJ, Krug K, et al. Microscaled proteogenomic methods for precision oncology. Nat Comm. 2020 Jan 27;11(1):532.

Udeshi ND, Mani DC, Satpathy S et al. Rapid and deep-scale ubiquitylation profiling for biology and translational research. Nat Comm. 2020 Jan 17;11(1):359.

Weiner BT, Narita T, Satpathy S, et al. Time-resolved analysis reveals rapid dynamics and broad scope of the CBP/p300 acetylome. Cell. 2018 Jun 28;174(1):231-244.e12. D

Satpathy S, Wagner SA, Beli P, et al. Systems-wide analysis of BCR signalosomes and downstream phosphorylation and ubiquitylation. Mol Syst Biol. 2015 Jun 2;11(6):810.

Shankha Satpathy, Ph.D.

Shankha Satpathy is a group leader in the Proteomics Platform at the Broad Institute of MIT and Harvard. As part of the CPTAC consortium, Satpathy leads several clinical proteomics and proteogenomic projects. Of note was the development of a proteogenomics workflow for core-needle biopsy and its application in clinical trials, and the comprehensive proteogenomic characterization of lung adenocarcinoma and lung squamous cell carcinoma that Satpathy co-led with research groups within the CPTAC consortium. As part of the proteomics team at Broad, he is also involved in several proteomics technology development areas, and also contributes to academic- and industry-partnered collaborative projects using mass spectrometry and other proteomic tools to investigate interesting biological questions with potential translational impact. His work intersects multiple disciplines and involves both basic scientists and clinicians.

Satpathy joined the Broad in September 2017 as a postdoctoral associate in the laboratory of Steven Carr. Satpathy has been a research scientist since 2019, and a group leader in proteomics since July 2021. He conducted his doctoral research in the application of proteomics to decipher immune signaling pathways, at the Novo Nordisk Foundation Center for Protein Research in Copenhagen and earned his Ph.D. from the University of Copenhagen in 2017. He also holds a M.S. in biochemistry and molecular biology from the University of Calgary and a B.Tech. in biotechnology from Vellore Institute of Technology, India.

Contact Shankha Satpathy via email at

July 2021